Varcoe RL, Menting TP, Thomas SD, et al. - Researchers undertook this prospective, single‐arm study to conduct a long‐term assessment of an everolimus eluting, bioresorbable vascular scaffold (BVS) in the management of de novo atherosclerotic disease within crural arteries. This analysis involved 48 patients with chronic lower limb ischemia (56% male; mean age 82.1 ± 8.0 years, range 65–97). The deaths of 22 (45.8%) patients was reported during a mean follow‐up span of 35.2 ± 20.4 months. Findings of this long‐term analysis demonstrated that use of the absorb BVS below‐the‐knee afforded excellent rates of patency and freedom from target lesion revascularization. The foundation for the next generation of BVS to be assessed in infrapopliteal arteries is laid by this proof of concept study.